Retrospective study for optimal regimen of neoadjuvant chemotherapy for advanced epithelial ovarian cancers.

Retrospective study for optimal regimen of neoadjuvant chemotherapy for advanced epithelial ovarian cancers. - SGSG-017

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000039539

Enrollment

300

Registered

2020-02-21

Start date

2020-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced epithelial ovarian, fallopian tube, and peritoneal cancers.

Interventions

None listed

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Patients with advanced epithelial ovarian, fallopian tube, or peritoneal cancer treated in Japan between January 2007 and December 2016 who underwent NAC (TC, dose-dense TC, weekly-TC, TC+BEV) at least 3 cycles or more.

Exclusion criteria

Exclusion criteria: 1) Patients with sarcomatous components (including carcinosarcoma). 2) Patients with borderline malignancy. 3) Patient who underwent primary debulking surgery for epithelial ovarian cancer without NAC.

Design outcomes

Primary

Measure	Time frame
Progression free survival	—

Countries

Japan

Contacts

Public ContactTakashi Shibutani

Hyogo Cancer Center Gynecologic Oncology

t-shibu@hp.pref.hyogo.jp0789291151

Outcome results